KR-333

KR-333 is an investigational **mRNA-based oncolytic and immunomodulatory cancer therapeutic** being developed by **Kernal Biologics** for **neoplasms**, particularly tumors that are resistant to checkpoint blockade such as anti-PD1 and anti-PD-L1 therapy. It has been described as an **onco-selective, oncolytic mRNA cocktail** designed to distinguish cancer cells from normal cells and to induce **immunogenic cell death**, thereby promoting antitumor immune activation. In preclinical anti-PD1-resistant tumor models, KR-333 reportedly reduced or eliminated tumors and improved survival when combined with anti-PD1 immunotherapy, supporting its positioning as a novel **mRNA cancer immunotherapy** in preclinical development.